Orphazyme (ORPH) Extension Should Not Raise Investor Concerns, Cowen Reiterates Outperform
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated an Outperform rating and $23.00 price target on Orphazyme (NASDAQ: ORPH) after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
